About Dr. Ginsberg
Dr. Ginsburg received his Ph.D. in Chemistry from the
City University of New York
and his law degree from
where he was a Harlan Fiske Stone Scholar. He was elected to Phi Beta Kappa at the
City College of New York
and to the scientific research honor society Sigma Xi at CUNY.
Dr. Ginsburg has spent most of his career as corporate counsel representing large and small pharmaceutical, biotechnology, chemical and consumer products companies. His last position was at Pfizer Inc., where he served as Head of the New York Patent Department which dealt with several blockbuster products, including Viagra and Chantix. He represented Pfizer on the intellectual property committees of the National Association of Manufacturers, the Chemical Manufacturers Association and the Biotechnology Industry Organization. Dr. Ginsburg has lectured widely on pharmaceutical and biotechnology patent prosecution and licensing at the Practicing Law Institute and Columbia Law School . Prior to his twenty year career at Pfizer, Dr. Ginsburg was a senior attorney at Schering-Plough. He was subsequently recruited by Merck and then by the highly respected IP law firm, Fish & Neave.
Dr. Ginsburg is perhaps most well-known as the author of the patent covering Schering-Plough's hugely successful product Claritin. He also authored important patents covering Schering-Plough's highly successful alpha-interferon product.
Dr. Ginsburg has authored the patent application for Cellceutix anticancer product Kevetrin™, which has been filed in
the United States
and other countries and has advised Cellceutix on patent and licensing matters during the past few years.
Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings.